Intermittent use of G-CSF in AIDS-related granulocytopenia (G) (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Intermittent use of G-CSF in AIDS-related granulocytopenia (G) (Meeting abstract).

Ann Oncol; 3(Suppl 5):137 1992. Unique Identifier : AIDSLINE ICDB/93689689
Katz A; Levy GC; Albert Einstein Hosp., Sao Paulo, Brazil

Abstract: AIDS patients (pts) often develop leukopenia and G, either related to the HIV infection itself or associated with the use of myelosuppressive drugs such as AZT or DHPG. This common event further complicates the clinical course of the pts and may require temporary or definitive discontinuation of these drugs. This problem might become especially distressful in pts with neurologic manifestations of AIDS receiving AZT. From March 1991 to November 1991, we treated 7 adult AIDS pts with AZT-induced G (WBC less than 2500 cells/mm3 and absolute neutrophil count [ANC] less than 1200 cells/mm3). Four pts had neurological manifestations of AIDS. Pts initially received daily sc G-CSF at 4-5 ug/kg, until adequate counts were achieved (WBC count greater than 5000/mm3 and ANC greater than 3000/mm3). CBC was always checked immediately before each administration of G-CSF. These counts were usually achieved after 2-4 days of therapy. At this point, pts started on a maintenance therapy which consisted of the intermittent administration of the minimum dose of G-CSF required to maintain adequate WBC and ANC. We found that all pts were capable of maintaining adequate counts while receiving G-CSF 2-3x a wk, at doses ranging from 150 to 300 ug/day. The use of G-CSF enabled us to use AZT at the same dose, it being before the onset of myelosuppression. The G of AIDS pts is not periodic and transient as the chemotherapy-related G, and therefore, special schedules of G-CSF will have to be devised for these pts.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Agranulocytosis/CHEMICALLY INDUCED/*THERAPY Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Human Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE ABSTRACT
930430
M9340818

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .